Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: The case of rosiglitazone

American Heart Journal

Volumn 156, Issue 1, 2008, Pages 23-30

  Hernandez, Adrian V ^a   Walker, Esteban ^a   Ioannidis, John P A ^b,c   Kattan, Michael W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF IOANNINA   (Greece)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ISRADIPINE; METFORMIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; ROSIGLITAZONE; SULFONYLUREA;

ANALYTIC METHOD; ANGINA PECTORIS; BLEEDING; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE TACHYCARDIA; HUMAN; META ANALYSIS; METHODOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIVITY ANALYSIS; SIDE EFFECT; SINUS TACHYCARDIA; STATISTICAL ANALYSIS; STROKE; SUDDEN DEATH; SYNCOPE; SYSTEMATIC REVIEW;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RARE DISEASES; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THIAZOLIDINEDIONES;

EID: 45649084853     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.03.002     Document Type: Review

References (42)

1. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
2. Psaty B.M., and Furberg C.D. Rosiglitazone and cardiovascular risk. N Engl J Med 356 (2000) 2522-2524
3. The Lancet. Rosiglitazone: seeking a balanced perspective. Lancet (2007) 10.1016/S0140-6736(07)60787-9 [published online May 23]
4. Home P.D., Pocock S.J., Beck-Nielsen H., et al., for the RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 357 (2007) 28-38
5. Nathan D.M. Rosiglitazone and cardiotoxicity-weighing the evidence. N Engl J Med 357 (2007) 64-66
6. Psaty B.M., and Furberg C.D. The record of rosiglitazone and the risk of myocardial infarction. N Engl J Med 357 (2007) 67-69
7. Krall R.L. Cardiovascular safety of rosiglitazone. Lancet 369 (2007) 1995-1996
8. Fuster V., and Farkouh M.E. Faster publication isn't always better. Nat Clin Pract Cardiovasc Med 4 (2007) 345
9. GlaxoSmithKline. Study no. ZM2005/00181/01; Avandia Cardiovascular Event Modeling Project. Available at:. http://ctr.gsk.co.uk/Summary/Rosiglitazone/III_CVmodeling.pdf) Accessed October 2, 2007
10. Diamond G.A., Bax L., and Kaul S. Uncertain effects of rosiglitazone on the risk of myocardial infarction and cardiovascular death. Ann Intern Med 147 (2007) 578-581
11. Bracken M.B. Rosiglitazone and cardiovascular risk. N Engl J Med 357 (2007) 937-938
12. Shuster J.J., Jones L.S., and Salmon D.A. Fixed vs. random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death. Stat Med 26 (2007) 4375-4385
13. Singh S., Loke Y.K., and Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone. A meta-analysis. JAMA 298 (2007) 1189-1195
14. Lago R.M., Singh P.P., and Nesto R.W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis if randomized clinical trials. Lancet 370 (2007) 1129-1136
15. Ross S.D., Kuperlnick B., Kumashiro M., et al. Risk of serious adverse events in hypertensive patients receiving isradipine: a meta-analysis. J Hum Hypertens 11 (1997) 743-751
16. Konstam M.A., Weir M.R., Reicin A., et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 104 (2001) 2280-2288
17. Jüni P., Narty L., Reichenbach S., et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364 (2004) 2021-2029
18. Salpeter S.R., Ormiston T.M., and Salpeter E.E. Cardiovascular effects of β-agonists in patients with asthma and COPD-a meta-analysis. Chest 125 (2004) 2309-2321
19. Kearney P.M., Baigent C., Godwin J., et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332 (2006) 1302-1308
20. Caldwell B., Aldington S., Weatherall M., et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 99 (2006) 132-140
21. White B., West C.R., Borer J.S., et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized controlled trials. Am J Cardiol 99 (2007) 91-98
22. Chen L.C., and Ashcroft D.M. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials. Pharmacoepidemiol Drug Saf 16 (2007) 762-772
23. In: Higgins J.P.T., and Green S. (Eds). Cochrane handbook for systematic reviews of interventions 4.2.6 [updated September 2006]. The Cochrane Library, Issue 4 (2006), John Wiley & Sons, Ltd, Chichester, UK 126-146
24. Bradburn M.J., Deeks J.J., Berlin J.A., et al. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 26 (2007) 53-77
25. Yusuf S., Peto R., Lewis J., et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Med 27 (1985) 335-371
26. McQuay H.J., and Moore R.A. Using numerical results for systematic reviews in clinical practice. Ann Intern Med 126 (1997) 720-721
27. Deeks J.J. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med 21 (2002) 1575-1600
28. Papanikolaou P.N., Christidi G.D., and Ioannidis J.P. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ 174 (2006) 635-641
29. Hernandez A.V., Westerhout C.M., Steyerberg E.W., et al. Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups. Heart 93 (2007) 450-455
30. Kahn S.E., Haffner S.M., Heise M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 (2006) 2427-2443 [Erratum, N Engl J Med 2007;356:1387-8.]
31. Gerstein H.C., Yusuf S., Bosch J., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 368 (2006) 1096-1105 [Erratum, Lancet 2006;368:1770]
32. Sweeting M.J., Sutton A.J., and Lambert P.C. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 23 (2004) 1351-1375
33. Nissen S.E., and Wolski K. Rosiglitazone and cardiovascular risk. N Engl J Med 357 (2007) 939-940
34. Ioannidis J.P., Chew P., and Lau J. Standardized retrieval of side effects data for meta-analysis of safety outcomes. J Clin Epidemiol 55 (2002) 619-626
35. Lau J., Ioannidis J.P., and Schmid C.H. Summing up evidence: one answer is not always enough. Lancet 351 (1998) 123-127
36. Ioannidis J.P.A. Why most published research findings are false. PLoS Med 2 (2005) e124
37. Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer. Worldwide evidence 1985-1990 Vol. 1 (1990), Oxford University Press, Oxford 12-18
38. Hauben M., Reich L., Van Puijenbroek E.P., et al. Data mining in pharmacovigilance: lessons from phantom ships. Eur J Clin Pharmacol 62 (2006) 967-970
39. Jorgensen A.W., Hilden J., and Gotzsche P.C. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ 333 (2006) 782
40. Ioannidis J.P., and Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 285 (2001) 437-443
41. Papanikolaou P.N., and Ioannidis J.P. Availability of large-scale evidence on specific harms from systematic reviews of randomized trials. Am J Med 117 (2004) 582-589
42. Ioannidis J.P., Evans S.J., Gotzsche P.C., et al., CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 141 (2004) 781-788